Literature DB >> 836017

Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci.

C Watanakunakorn, C Glotzbecker.   

Abstract

The in vitro activity of nafcillin, oxacillin, and methicillin alone and in combination with gentamicin and tobramycin against 30 strains of enterococci was investigated. The penicillinase-resistant penicillins were less active than penicillin and ampicillin against the enterococci. Nafcillin was more active than oxacillin and methicillin. Sixty-six percent of strains were inhibited by nafcillin at 6.25 mug/ml, but none was inhibited by oxacillin and methicillin at the same concentration. At 12.5 mug/ml, 83, 16, and 0% were inhibited by nafcillin, oxacillin, and methicillin, respectively. By using a variety of criteria and analyses, it was shown that none of the antibiotic combinations studied demonstrated enhanced killing of all strains of enterococci. Nafcillin-gentamicin was the best combination, and enhanced killing was demonstrated against most strains. Oxacillin was more effective than methicillin when combined with gentamicin. Tobramycin was probably less effective than gentamicin in combination with the penicillinase-resistant penicillins against enterococci.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 836017      PMCID: PMC351923          DOI: 10.1128/AAC.11.1.88

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Antibiotic synergism against group D streptococci in the treatment of endocarditis.

Authors:  R W Ruhen; J H Darrell
Journal:  Med J Aust       Date:  1973-07-21       Impact factor: 7.738

2.  Synergy of penicillin and gentamicin against Enterococci.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

3.  Activity of amoxycillin against enterococci and synergism with aminoglycoside antibiotics.

Authors:  E J Russell; R Sutherland
Journal:  J Med Microbiol       Date:  1975-02       Impact factor: 2.472

4.  Characteristics of bacterial endocarditis in heroin addicts in Detroit.

Authors:  M R El-Khatib; F M Wilson; A M Lerner
Journal:  Am J Med Sci       Date:  1976 Mar-Apr       Impact factor: 2.378

5.  Enterococcal endocarditis in heroin addicts.

Authors:  N E Reiner; K V Gopalakrishna; P I Lerner
Journal:  JAMA       Date:  1976-04-26       Impact factor: 56.272

6.  Discrepancy between carbenicillin and ampicillin activities against enterococci and Listeria.

Authors:  G H McCracken; J D Nelson; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

7.  Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin.

Authors:  R C Moellering; C Wennersten; A J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

8.  In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci.

Authors:  H J Harwick; G M Kalmanson; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

9.  Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci.

Authors:  C Watanakunakorn; C Bakie
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

10.  Synergism of carbenicillin and gentamicin against enterococci.

Authors:  R D Libke; C Regamey; J T Clarke; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1973-11       Impact factor: 5.191

View more
  2 in total

1.  Penicillinase-resistant penicillins plus gentamicin in experimental enterococcal endocarditis.

Authors:  L J Lincoln; A J Weinstein; M Gallagher; E Abrutyn
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

Review 2.  The epidemiology of enterococci.

Authors:  C Chenoweth; D Schaberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.